Clinical Trial Update: Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients [NA]

View source ↗

Summary

A completed clinical trial evaluated Fluorine-18-labeled fluoro-misonidazole PET imaging to detect tumor hypoxia in locally advanced rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Fluorine-18-labeled fluoro-misonidazole (fluoro-misonidazole)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Colorectal Cancer | NA | Status: COMPLETED | Results posted: 2025-05-09